Investor Presentation H1 2023
115
Investor presentation
First six months of 2023
International Operations at a glance.
Novo NordiskⓇ
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
DKK
billion
19%
17%
Novo Nordisk reported sales
First half of 2023
Sales
(mDKK)
Growth²
Injectable GLP-13
15,531
46%
250
600
100%
Rybelsus®
3,411
214%
Total GLP-1
18,942
62%
200
80%
38.8%1
GLP-1
Total insulin4
19,413
-2%
400
720
150
60%
Other Diabetes care5
1,095
-18%
Insulin
Diabetes care
39,450
20%
587
2.5%1
487
100
40%
200
Obesity care
3,989
66%
50
OAD
20%
Diabetes & Obesity
43,439
24%
9.2%1
care
0
0
0%
2021
2030
Population with diabetes
Diabetes growth rate
2045
May
2018
May
2023
Rare disease?
Total
5,268
-17%
48,707
17%
-GLP-1 MS
-Insulin MS
-OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific; Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
May 2023: Novo Nordisk 51%, Others 49%; Competitor GLP-1 value market shares,
as of May 2023: Novo Nordisk 67%, Other 33%; OAD: Oral anti-diabetic; MS: Market
share; Source: IQVIA MAT, May 2023 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, OzempicⓇ;
4 Comprises Tresiba®, XultophyⓇ, Levemir®, Ryzodeg®, Novo Mix®, Fiasp® and
NovoRapidⓇ: 5 Comprises Novo Norm® and needles; 6 Obesity care comprises
SaxendaⓇ and Wegovy®: 7 Comprises primarily Novo Seven®, Novo Eight®
NovoThirteenⓇ, Refixia®, Esperoct®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation